Drugs / Tasisulam
Trials 13
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 17 trials | ||||||
| Phase 1 | NCT01209832 | Sep 2010 → Jan 2011 | cancer of unknown primary site | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01185548 | Jul → Dec 2010 | lymphoma | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01214668 | Jan 2009 → Feb 2012 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT00718159 | Aug 2008 → Dec 2011 | acute myeloid leukemia, essential thrombocythemia | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01258348 | Jul 2008 → Feb 2012 | renal cell carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 1 | NCT01284335 | Jul 2008 → Oct 2012 | cancer | Eli Lilly and Company | Terminated | No outcome recorded |
| Phase 1 | NCT01215916 | Feb 2008 → Dec 2011 | cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT00992225 | Sep 2009 → Apr 2011 | breast cancer | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00490451 | Aug 2007 → Feb 2010 | soft tissue sarcoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00428610 | Feb 2007 → Feb 2011 | fallopian tube cancer, ovarian cancer, primary peritoneal carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00383292 | Nov 2006 → Sep 2011 | metastatic melanoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 2 | NCT00363766 | Sep 2006 → Oct 2008 | non-small cell lung carcinoma | Eli Lilly and Company | Completed | No outcome recorded |
| Phase 31 trial · 1 missed | ||||||
| Phase 3 | NCT01006252 | Dec 2009 → Mar 2011 | melanoma | Eli Lilly and Company | Terminated | Missed primary |
News releases announcing trial results or a regulatory action · 2
| Date | Issuer | Release |
|---|---|---|
| 2010-12-13 | Eli Lilly and Company | Regulatory Lilly Suspends Phase III Trial in Metastatic Melanoma lilly.com ↗
Lilly, in consultation with an independent data monitoring committee, recommended a "full clinical hold," because of safety concerns. |
| 2010-05-20 | Eli Lilly and Company | Results Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths lilly.com ↗
The median progression-free survival was 2.6 months and the median overall survival was 9.6 months. |
All press releases naming this drug 2 releases
| Date | Issuer | Release |
|---|---|---|
| 2010-12-13 | Eli Lilly and Company | Lilly Suspends Phase III Trial in Metastatic Melanoma lilly.com ↗ |
| 2010-05-20 | Eli Lilly and Company | Lilly Presents New Data in Advanced Melanoma - A Difficult-To-Treat Cancer That Causes Majority of Skin Cancer Deaths lilly.com ↗ |
Evidence & citations 9 cited values
Every value below carries the sentence it was read from. 14 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | tasisulam | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00383292 ↗ |
| Known as | LY-573636.NA | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110587 ↗ |
| Known as | LY573636 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01215916 ↗ |
| Known as | LY573636-sodium | “The goal of this study is to determine the dose of LY573636-sodium (hereafter referred to as LY573636) that can be administered safely in combination with liposomal doxorubicin...” NCT01214668 ↗5“The primary objective is to estimate the time to progressive disease for patients who receive LY573636-sodium (hereafter referred to as LY573636) after two previous treatments...” NCT00363766 ↗ “The primary purpose of the study is to estimate the time from the first dose of LY573636-sodium (hereafter referred to as LY573636) to the date your physician determines that...” NCT00490451 ↗ “LY573636-sodium (LY573636) is administered every 28 days until disease progression or other criteria for participant discontinuation are met.” NCT00428610 ↗ |
| Known as | TASISULAM SODIUM | ChEMBL registry synonym — accepted as the source's own label CHEMBL2110587 ↗ |
| Action | Inhibit | “inhibitor of CYP2C9” NCT01185548 ↗ |
| Modality | Small molecule | — CHEMBL2110587 ↗ |
| Route | Intravenous | “Patients will receive an intravenous infusion of study drug once every 21 days.” NCT00363766 ↗ |
| Target | CYP2C9 | “inhibitor of CYP2C9” NCT01185548 ↗ |